Oncolytics Biotech is trading at $0.50, up 5.64% in pre-market, with its patent announcement a plausible but unconfirmed overnight catalyst. - On October 12, the company announced that a pelareorep cancer-immunotherapy method-of-use patent had issued in several countries. - A U.S. patent is expected soon, and planned protections could extend into the late 2040s. - The company did not directly attribute the share move to the update; no separate confirmed pre-market explanation was found.